Navigation Links
TDS restates years of revenues, shows slight profit drop

Phone and data company TDS, also the corporate parent of U.S. Cellular, said its revenues for the last quarter were $1 billion, an increase over results from last year that it had to restate due to accounting problems.

Net income for the quarter was $41.5 million, down from $43.3 million in the same quarter a year ago.

TDS said in November 2005 it would have to restate some resul......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 04/26/06


Page: 1

Related biology technology :

1. UW System says goodbye to Lawson after 5 years, $26 million
2. Space port could open in Sheboygan in next 10 years
3. Internet Scout celebrates 10 years on web, eyes new project launch
4. Food microbiology symposium will mark 25 years
5. UW engineering career fair sees highest attendance in four years
6. Northwoods Software co-owner distills 30 years of business experience
7. SupraNet marks off 10 years as an Internet service provider
8. Blurb shows that print still captures imaginations
9. Kauffman study shows consistent entrepreneurial growth
10. Directory shows high-tech growth spurt in Dane Co.
11. Stem cell therapy shows visionary promise

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: TDS restates years revenues shows slight profit drop

(Date:11/24/2009)...ntly approved the Promega PowerPlex 16 HS System f...ing DNA records for the National DNA Index System....) -- The FBI recently approved the Promega PowerP...ticipating in, or generating DNA records for, the ...ontains more than seven million profiles and has a...
(Date:11/24/2009)...irstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),thegl...cedthatithassubmittedaMAAtotheEuropeanMedicinesAge...menttherapyindevelopment,forthetreatmentofType1Gau...velaglucerasealfathathasbeensubmitted,withprevious...edonaglobalsupplyshortageofthecurrentlyapprovedand...
(Date:11/24/2009)...ire/--HealthRoboticstodayannounced,thatithasformed...tors.ThisrecentlyformedToronto-basedcompanywillope...arket,install,andsupport,HealthRobotics,i.v.Roomof...ductofferingsi.v.STATION(TM),i.v.SOFT(TM),andOMM(T...nceonan"asneeded,basis"toitsstrategicpartnershipsw...
(Date:11/24/2009)...tCall/--CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CT...yHealthCareConference.TheconferencewillbeheldDecem...presentonTuesday,December1at11:00a.m.EasternTimein...tionwillbeavailableat www.celltherapeutics.com ,an...erJaffrayHealthCareConference,NewYorkPalaceHotel,H...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
... (Nasdaq: DCTH ) today announced the appointment...rectors. Dr. Stoll is Executive Chairman of Corte...ology company specializing in the treatment of cen... http://www.newscom.com/cgi-bin/prnh/20081118/NY46...toll worked as a consultant to several east coast ...
...orporation,(Nasdaq: PRXL ), a leading global bio...hat it has established an alliance with Safe Imple...onal, the world,s largest network of,clinical site...oke. Through,this alliance, PAREXEL,s clients bene...r sites located in 40 countries, which are dedicat...
...armaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) an...ons following the failure of the Bicifadine Phase ...employment of 9 employees,representing 75% of its ...sible for seeking potential assets or a company to...on and/or disposition of XTL,s assets. , Cau...
Other Biology Technology:Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies 2PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies 3PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies 4
(Date:11/23/2009)...RE, Calif. - By producing some of the highest reso...faces, scientists have a deeper understanding how ...research may lead to a new treatment for kidney st...ppears in the Nov. 23 online edition of the journa... , explores how peptides interact with mineral sur...
(Date:11/23/2009)...MINGHAM, Ala. A new study by University of Alabam...mass index (BMI) and co-existing medical condition...ival observed among African-Americans compared to ...s published online Nov. 23 in Cancer , a journal ...dicates that although BMI and co-morbidity are ind...
(Date:11/23/2009)...GN, Ill. Two new studies reveal in unprecedented ...ules to assemble new proteins and guide them towar...es used molecular dynamics flexible fitting (MDFF)...wo prominent molecular partners. , The first st...iences , concerns the intimate signaling between t...
Breaking Biology News(10 mins):Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 1Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 1Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 7Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 1Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 2Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 3Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 4Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 5Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 6Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 7Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 8Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 9Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 10Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 11Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 12Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 13Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 14Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 15Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 16Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 17Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 18
...09-Oakland, Calif.- Children,s Hospital & Research...n the country to use groundbreaking technology tha... pediatric hospitals. This new method uses smart-c... or credit cards at the supermarket or gas station... starts with a respiratory therapist who takes a t...
...M, N.C. A discovery made by researchers at Wake F... mice may help explain how some people without a g...disorder. , In a study published this month in th...yne W. Godwin, Ph.D., a professor of neurobiology ...at a gene, already known to predispose people who ...
...ler University and the Institute for Advanced Stud...tiative in biology supported by a $10 million gift...y. The initiative, which builds on the complementa...will involve biologists, mathematicians, physicist...nd theoretical approaches to biological problems. ...
Other Biology News:Children's Hospital Oakland is first pediatric hospital to use 'laboratory-on-a-card' technology 2Researchers discover that gene switches on during development of epilepsy 2Researchers discover that gene switches on during development of epilepsy 3$10 million Simons Foundation gift supports new initiative with Institute for Advanced Study 2
... a base medium for preparation of minimal and synt...ulfate but does not contain amino acids. Both bulk... Each pouch contains reagents to prepare 500 ml of...r S. cerevisiae media. Store at 15C to 30C. Guaran...
...ons are cytopathic effect inhibition assays, also ...tion assay measures the antibody's ability to neut...pes include; tissue culture supernatents; serum an...t is defined as the quantity of interferon require...
Rabbit Anti-Shigella Polyclonal Antibody, Unconjugated from GeneTex
...dy is a mouse monoclonal antibody (IgG1) with high...(GST) domain from S. japonicum . This purified ant...ntaining the GSTTag sequence expressed in E. coli ...nslation systems by Western blotting, immunofluore...
Biology Products: